CONTENTS:
- The need for research addressing alcohol use disorder and diabetes [Editorial]. Walter K.N., Wagner J.A., Cengiz E., Tamborlane W.V., Petry N.M., p. 763-765.
- Announcing changes to randomized controlled trial (RCT) registration requirements and our new Short Report format [Editorial note]. West R., p. 766.
- Which medications are suitable for agonist drug maintenance? [For debate]. Darke S., Farrell M., p. 767-774.
- Abstinence or maintenance treatment in substance use disorders? Walter M., Soyka M., p. 775-776.
- Substitution treatment in addiction: there is more than one way… Lingford-Hughes A., p. 776-777.
- A few words on 'Which medications are suitable for agonist drug maintenance?'. Shoptaw S., p. 778-779.
- What matters is more than just the choice of pharmaceutical agent. Kidd B., Day E., Strang J., p. 779-781.
- Response to commentaries on 'Which medications are suitable for agonist drug maintenance'. Darke S., Farrell M., p. 781-782.
- Meta-analysis on the effectiveness of alcohol screening with brief interventions for patients in emergency care settings. Schmidt C.S., Schulte B., Seo H.-N., Kuhn S., O'Donnell A., Kriston L., et al., p. 783-794.
- Effectiveness of motivational interviewing to reduce illicit drug use in adolescents: a systematic review and meta-analysis. Li L., Zhu S., Tse N., Tse S., Wong P., p. 795-805.
- Validity of the alcohol purchase task: a meta-analysis. Kiselica A.M., Webber T.A., Bornovalova M.A., p. 806-816.
- A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada. Zur R.M., Zaric G.S., p. 817-831.
- Cost-effectiveness of motivational intervention with significant others for patients with alcohol misuse. Shepard D.S., Lwin A.K., Barnett N.P., Mastroleo N., Colby S.M., Gwaltney C., et al., p. 832-839.
- Commentary on Zur & Zaric and Shepard et al. (2016): Cost-effectiveness of SBI for alcohol - where are we and where do we want to go? Barbosa C., Cowell A., p. 840-842.
- Assessing elements of a family approach to reduce adolescent drinking frequency: parent-adolescent relationship, knowledge management and keeping secrets. McCann M., Perra O., McLaughlin A., McCartan C., Higgins K., p. 843-853.
- Trajectories of drinking urges and the initiation of abstinence during cognitive-behavioral alcohol treatment. Hallgren K.A., McCrady B.S., Epstein E.E., p. 854-865.
- Malmö Treatment Referral and Intervention Study (MATRIS) - effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. Brabäck M., Nilsson S., Isendahl P., Troberg K., Bradvik L., Hakansson A., p. 866-873.
- Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment. Mokri A., Chawarski M.C., Taherinakhost H., Schottenfeld R.S., p. 874-882.
- Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. Bird S.M., McAuley A., Perry S., Hunter C., p. 883-891.
- Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Lo-Ciganic W.-H., Gellad W.F., Gordon A.J., Cochran G., Zemaitis M.A., Cathers T., et al., p. 892-902.
- Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial. Sigmon S.C., Miller M.E., Meyer A.C., Saulsgiver K., Badger G.J., Heil S.H., et al., p. 903-912.
- Childhood maltreatment, personality disorders and 3-year persistence of adult alcohol and nicotine dependence in a national sample. Elliott J.C., Stohl M., Wall M.M., Keyes K.M., Skodol A.E., Eaton N.R., et al., p. 913-923.
- When psychopathology matters most: identifying sensitive periods when within-person changes in conduct, affective and anxiety problems are associated with male adolescent substance use. Cerda M., Prins S.J., Galea S., Howe C.J., Pardini D., p. 924-935.
- Dependence measures based on hookah smokers' experiences and context are needed. Myers K., Ward K.D., Maziak W., p. 936-936.
- Public health implications of waterpipe tobacco use in the United States warrant initial steps towards assessing dependence. Sidani J.E., Shensa A., Shiffman S., Switzer G.E., Primack B.A., p. 937-938.
- Author's response on Arria (2016): Intention matters - using the terminology 'pharmacological neuroenhancement' as a behavioural definition based on the assumed functionality. Maier L.J., Haug S., Schaub M.P., p. 938-939.
- Why not publish all research that passes review? Fagerström K., Hughes J.R., p. 939-940.